radiopharmtheranostics.com (RADX): Forward P/S Multiple
Outsourcing production and testing allows Radiopharm Theranostics (RADX) to focus on developing targeted therapies, which determines the dynamics of the future price-to-sales ratio. New FDA approvals and successes in cancer treatment support this growth, while strong brand authority among oncologists strengthens its position. 4.70 serves as the current parameter value, capturing the existing trend on the forecast multiple chart.
Financial and market metric breakdowns for radiopharmtheranostics.com (RADX)
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Debt to Equity Radiopharm Theranostics|RADX - Long-Term Liabilities to Equity|Short-Term Debt to Capital Radiopharm Theranostics Limited|RADX - Aggregate Debt Obligations|Debts to Book Capitalization Radiopharm Theranostics Limited|RADX - Company Long-Term Debts|Company Short-Term Debt Radiopharm Theranostics|Quick Liquidity radiopharmtheranostics.com
- financial results and valuation multiples details:
RADX - Net Income|Future Profit Radiopharm Theranostics|RADX - Company Value to Net Income|Projected Price to Earnings Radiopharm Theranostics|RADX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Radiopharm Theranostics Limited|RADX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Radiopharm Theranostics|RADX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months radiopharmtheranostics.com|RADX - Earnings per share increase in current year|Earnings growth forecast for next year Radiopharm Theranostics
- sales volume and revenue indicators:
Summary company analysis:Radiopharm Theranostics RADX
Isotope synthesis in laboratories and the design of new capacities at Radiopharm Theranostics (RADX) lay the foundation for future revenue growth. By analyzing the company's expected P/S, an investor compares current market capitalization with projected sales, which allows for the identification of asset value inflection points and an assessment of whether the market price is justified relative to the scaling of the business's production potential.
Competitors of Radiopharm Theranostics
Forward P/S Multiple ONC (BeiGene)|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RevMed - Forward P/S Multiple|AAPG (Ascentage Pharma Corp) - Market Cap to Projected Revenue|CGON: Forward P/S Multiple|URGN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bicara Therapeutics|Market Cap to Future Revenue Ratio Personalis Inc PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|DCTH: Future Price to Revenue|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|Forward Price to Sales AURA|Candel - Forward P/S Multiple|ARAY - Forward P/S Multiple|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|Actuate Therapeutics Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Citius Oncology, Inc.|Forward Price-to-Revenue Multiple TuHURA (HURA)|Forward Price-to-Revenue Multiple TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Forward Price to Sales|Aadi Bioscience - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TCRX (TScan Therapeutics Inc)|Champions Oncology Corp - Forward P/S Multiple|Forward Price to Sales XBIT (XBiotech Inc.)|CVM: Forward P/S Multiple|Market Cap to Future Revenue Ratio OS Therapies Inc. (OSTX)|Price-to-Projected Revenue Ratio Artiva Biotherapeutics Inc.|ANL: Forward Price to Sales|Forward P/S Multiple VERU|Forward P/S Multiple tempesttx.com (TPST)|Price-to-Projected Revenue Ratio Xilio Therapeutics XLO|RENB: Market Cap to Projected Revenue|MURA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|GDTC - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CRIS|APLM (Apollomics Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple THAR|Market Cap to Expected Sales Ratio advanbiomed.com|Forward P/S Multiple GNPX (Genprex, Inc.)|CLDI - Forward Price-to-Revenue Multiple|SBFM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Xenetic Biosciences XBIO|Salarius (SLRX) - Price-to-Projected Revenue Ratio|Kitov Pharma - Forward Price to Sales|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward P/S Multiple beigene.com|Forward P/S Multiple CKPT|elevationoncology.com - Market Cap to Projected Revenue|iCAD - Forward Price-to-Revenue Multiple|IKNA: Market Cap to Projected Revenue|Notable Labs, Ltd. - Forward P/S Multiple|Viracta Therapeutics (VIRX) - Forward Price-to-Revenue Multiple|MOR: Forward P/S Multiple|NAYA Biosciences Inc (NAYA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
